Literature DB >> 7432065

Pathology of vascular sensorineural hearing impairment.

A Belal.   

Abstract

Circulatory disorders, which are well documented in most parts of the human body, are not well documented in the inner ear, although they are expected to occur. It has been previously shown that experimental occlusion of the labyrinthine artery in animals results in severe degenerative changes, fibrosis, and new bone formation in the cochlea. Accordingly, this paper presents presumptive evidence that depriving the human cochlea of its blood supply after surgical removal of an acoustic tumor results in severe degenerative changes that progress to total ossification of the cochlear spaces. This paper also discusses similar changes seen in temporal bones of two patients with sudden sensorineural hearing impairment. Based on these observations, the author concludes that occlusive arterial disease, whether thrombotic, embolic, or spastic, plays a role in some sudden sensorineural hearing losses. Cochlea ossification, detected by polytomography, suggests a vascular etiology of the hearing impairment. Treatment with vasodilator drugs and anticoagulants is justified in these cases until a better diagnostic protocol is developed to eliminate other causes.

Entities:  

Mesh:

Year:  1980        PMID: 7432065     DOI: 10.1288/00005537-198011000-00011

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  Positive family history of idiopathic sudden sensorineural hearing loss.

Authors:  A Gäckler; A K Eickelmann; D Brors; S Dazert; J T Epplen; E Kunstmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-01       Impact factor: 2.503

2.  Cochlear obliteration after translabyrinthine vestibular schwannoma surgery.

Authors:  Caroline Beutner; Christian Mathys; Bernd Turowski; Jörg Schipper; Thomas Klenzner
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-11       Impact factor: 2.503

3.  The pathology of idiopathic sudden sensorineural hearing loss.

Authors:  H F Schuknecht; E D Donovan
Journal:  Arch Otorhinolaryngol       Date:  1986

4.  Cochlear Patency after Translabyrinthine and Retrosigmoid Vestibular Schwannoma Surgery.

Authors:  Huibert Frans van Waegeningh; Elke Loos; Tony Van Havenbergh; Thomas Somers
Journal:  J Int Adv Otol       Date:  2020-04       Impact factor: 1.017

5.  Assessment of balance and vestibular functions in patients with idiopathic sudden sensorineural hearing loss.

Authors:  Jia Liu; Ren-Hong Zhou; Bo Liu; Yang-Ming Leng; Jing-Jing Liu; Dong-Dong Liu; Su-Lin Zhang; Wei-Jia Kong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-04-11

6.  Management of acute idiopathic sensorineural hearing loss: a survey of UK ENT consultants.

Authors:  S J Jarvis; V Giangrande; G John; A R D Thornton
Journal:  Acta Otorhinolaryngol Ital       Date:  2011-04       Impact factor: 2.124

7.  Correlation of Neutrophil-to-Lymphocyte Ratio and the Dilation of the Basilar Artery with the Potential Role of Vascular Compromise in the Pathophysiology of Idiopathic Sudden Sensorineural Hearing Loss.

Authors:  Dae-Woong Kang; Seul Kim; Woongsang Sunwoo
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

8.  Relationship between the drainage pattern of the dural venous sinuses and hearing recovery in patients with sudden sensorineural hearing loss.

Authors:  Jung Woo Park; Dong Hyun Kim; Tae Kyu Kang; Woongsang Sunwoo
Journal:  Sci Rep       Date:  2020-04-07       Impact factor: 4.379

Review 9.  Biomarkers Suggesting Favorable Prognostic Outcomes in Sudden Sensorineural Hearing Loss.

Authors:  Jeon Gang Doo; Dokyoung Kim; Yong Kim; Myung Chul Yoo; Sung Su Kim; Jeewon Ryu; Seung Geun Yeo
Journal:  Int J Mol Sci       Date:  2020-09-30       Impact factor: 5.923

10.  Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids: a protocol for randomized controlled trial.

Authors:  Weiming Hao; Liping Zhao; Huiqian Yu; Huawei Li
Journal:  Trials       Date:  2020-07-22       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.